A nested case-control study on treatment-related risk factors for early relapse of tuberculosis

被引:113
作者
Chang, KC
Leung, CC
Yew, WW
Ho, SC
Tam, CM
机构
[1] Grantham Hosp, TB & Chest Service, Dept Hlth, Hong Kong, Hong Kong, Peoples R China
[2] Grantham Hosp, TB & Chest Unit, Hong Kong, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Prince Wales Hosp, Sch Publ Hlth, Dept Community & Family Med, Hong Kong, Hong Kong, Peoples R China
关键词
logistic models; recurrence; risk factors; therapeutics; tuberculosis;
D O I
10.1164/rccm.200407-905OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
This nested case-control study aimed at evaluating treatment-related risk factors of relapse of tuberculosis under a service program of directly observed treatment. Out of 12,183 patients with pulmonary tuberculosis who completed treatment within I year, 113 relapsed within 30 months after commencement of therapy. The overall 30-month relapse rate was 0.9% (95% confidence interval [CI] 0.8-1.1%). On matching 113 cases with 226 control subjects in a conditional logistic model, thrice-weekly treatment increased the risk of relapse in comparison with daily treatment (odds ratio 3.92, 95% CI 1.78-8.63), whereas prolonging both intensive phase and overall treatment by 50% or more protected against relapse (odds ratio 0.24, 95% CI 0.08-0.70). When pretreatment culture was positive and cavitation was absent, the 30-month relapse rate for standard thrice-weekly regimen was 1.1% (95% CI 0.6-2.0%). The corresponding rates in the presence of cavitation were 7.8% (95% CI 4.0-14.6%) for standard thrice-weekly regimen; 3.3% (95% CI 1.9-5.5%) for standard daily regimen; 0.5% (95% CI 0.1-2.6%) for extended thrice-weekly regimen; and 0.4% (95% CI 0.1-0.9%) for extended daily regimen. Further studies are required to reduce the risk of relapse under program settings.
引用
收藏
页码:1124 / 1130
页数:7
相关论文
共 24 条
[1]  
Aber V R, 1978, Bull Int Union Tuberc, V53, P276
[2]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[3]  
[Anonymous], 1976, Tubercle, V57, P105
[4]  
Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8
[5]   A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment [J].
Bock, NN ;
Sterling, TR ;
Hamilton, CD ;
Pachucki, C ;
Wang, YC ;
Conwell, DS ;
Mosher, A ;
Samuels, M ;
Vernon, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (11) :1526-1530
[6]  
*BRIT MED RES COUN, 1980, TUBERCLE, V61, P59
[7]  
BRITISH THORACIC ASSOCIATION, 1982, American Review of Respiratory Disease, V126, P460
[8]  
CAMPBELL MJ, 2001, STAT SQUARE 2 UNDERS, P51
[9]   Postantibiotic effects of antituberculosis agents alone and in combination [J].
Chan, CY ;
Au-Yeang, C ;
Yew, WW ;
Hui, M ;
Cheng, AFB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3631-3634
[10]   A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN [J].
COHN, DL ;
CATLIN, BJ ;
PETERSON, KL ;
JUDSON, FN ;
SBARBARO, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :407-415